Patents by Inventor Steven J. Shire

Steven J. Shire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS
    Publication number: 20190358323
    Abstract: The present application relates to highly concentrated antibody and protein formulations with, reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein.
    Type: Application
    Filed: February 7, 2019
    Publication date: November 28, 2019
    Inventors: Jun LIU, Steven J. SHIRE
  • REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS
    Publication number: 20190231875
    Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
    Type: Application
    Filed: November 21, 2018
    Publication date: August 1, 2019
    Inventors: Jun LIU, Steven J. SHIRE
  • Reduced-viscosity concentrated protein formulations
    Patent number: 10166293
    Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: January 1, 2019
    Assignees: Genentech, Inc., Novartis AG
    Inventors: Jun Liu, Steven J. Shire
  • High concentration antibody and protein formulations
    Patent number: 10034940
    Abstract: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: July 31, 2018
    Assignees: Genentech, Inc., Novartis AG
    Inventors: Jun Liu, Steven J. Shire
  • HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS
    Publication number: 20170049888
    Abstract: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein.
    Type: Application
    Filed: August 31, 2016
    Publication date: February 23, 2017
    Inventors: Jun LIU, Steven J. SHIRE
  • REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS
    Publication number: 20160367675
    Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which arc particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
    Type: Application
    Filed: August 31, 2016
    Publication date: December 22, 2016
    Inventors: Jun LIU, Steven J. SHIRE
  • Protein formulation
    Patent number: 9283273
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 15, 2016
    Assignee: GENENTECH, INC.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Treating a mammal with a formulation comprising an antibody which binds IgE
    Patent number: 9180189
    Abstract: A method of treating a mammal with a formulation comprising an antibody which binds IgE as described.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: November 10, 2015
    Assignee: GENENTECH, INC.
    Inventors: James Andya, Chung C. Hsu, Steven J. Shire, Sylvia Sau-Yan Wu
  • HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS
    Publication number: 20150225485
    Abstract: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein.
    Type: Application
    Filed: January 16, 2015
    Publication date: August 13, 2015
    Inventors: Jun LIU, Steven J. SHIRE
  • High concentration antibody and protein formulations
    Patent number: 8961964
    Abstract: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: February 24, 2015
    Assignee: Genentech, Inc.
    Inventors: Jun Liu, Steven J. Shire
  • REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS
    Publication number: 20150044198
    Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
    Type: Application
    Filed: March 7, 2014
    Publication date: February 12, 2015
    Applicants: Novartis AG, Genentech, Inc.
    Inventors: Jun LIU, Steven J. SHIRE
  • Reduced-viscosity concentrated protein formulations
    Patent number: 8703126
    Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: April 22, 2014
    Assignees: Genentech, Inc., Novartis AG
    Inventors: Jun Liu, Steven J. Shire
  • PROTEIN FORMULATION
    Publication number: 20130224185
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 29, 2013
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS
    Publication number: 20120076783
    Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
    Type: Application
    Filed: November 29, 2011
    Publication date: March 29, 2012
    Applicants: Novartis AG, Genentech, Inc.
    Inventors: Jun LIU, Steven J. Shire
  • Reduced-viscosity concentrated protein formulations
    Patent number: 8142776
    Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: March 27, 2012
    Assignees: Genentech, Inc., Novartis AG
    Inventors: Jun Liu, Steven J. Shire
  • HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS
    Publication number: 20120064086
    Abstract: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein.
    Type: Application
    Filed: June 21, 2011
    Publication date: March 15, 2012
    Applicants: NOVARTIS AG, GENENTECH, INC.
    Inventors: Jun LIU, Steven J. SHIRE
  • METHODS FOR TREATMENT OF ALLERGIC ASTHMA
    Publication number: 20110311520
    Abstract: Methods of treatment of allergic asthma with IgE antagonists, including anti-IgE antibodies, IgE variants, peptide antagonists, peptidomimetics and other small molecules, are described.
    Type: Application
    Filed: August 31, 2011
    Publication date: December 22, 2011
    Applicant: Genentech, Inc.
    Inventors: Robert B. Fick, Paula M. Jardieu, Monika B. Schoenhoff, Steven J. Shire
  • Protein Formulation
    Publication number: 20110236383
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Application
    Filed: June 8, 2011
    Publication date: September 29, 2011
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • METHODS OF TREATING IgE-MEDIATED DISORDERS COMPRISING THE ADMINISTRATION OF HIGH CONCENTRATION ANTI-IgE ANTIBODY FORMULATIONS
    Publication number: 20100158898
    Abstract: The present application relates to methods of treating IgE-mediated disorders comprising the administration of highly concentrated anti-IgE antibody formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration.
    Type: Application
    Filed: October 5, 2009
    Publication date: June 24, 2010
    Applicants: Genentech, Inc., Novartis AG
    Inventors: Jun LIU, Steven J. SHIRE
  • PROTEIN FORMULATION
    Publication number: 20100158899
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Application
    Filed: February 2, 2010
    Publication date: June 24, 2010
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu